Whitepapers

From Sequencing to Clinical Interpretation: The Infrastructure Gap in Genomic Medicine

Author: Rahila Sardar, PhD — Co-Founder and CEO  ·  Published: April 2026  ·  Reading time: ~14 min

Abstract

The cost of whole-genome sequencing reagents has fallen below $300 per genome by 2026, a reduction that outpaced Moore’s Law by several orders of magnitude. Despite this, the rate-limiting step in clinical genomics has shifted decisively from sequencing to interpretation. A whole-exome sequencing (WES) run produces 30,000–100,000 variants after quality filtering; a whole-genome sequencing (WGS) run produces 3–5 million. Translating this data into a clinically actionable report requires continuous integration of dynamically updated annotation databases (including ClinVar, gnomAD v4, OMIM, ClinGen, and HPO); application of evidence-based classification frameworks such as the ACMG/AMP guidelines; phenotype-driven prioritisation; standardised reporting; and scalable computational infrastructure simultaneously. This article describes these challenges in scientific and engineering terms, references key literature, and explains the design principles underlying the Vgen23 clinical genomics platform.

Keywords: clinical genomics · variant interpretation · ACMG classification · annotation pipelines · phenotype-genotype correlation · tertiary analysis · genomic reporting

1. Introduction: The Interpretation Bottleneck

The Human Genome Project produced the first reference sequence of the human genome over 13 years at a cost of approximately $2.7 billion. In the two decades since, advances in next-generation sequencing (NGS) technology, including short-read platforms such as Illumina NovaSeq X and long-read systems such as PacBio and Oxford Nanopore have reduced sequencing reagent costs to below $300 per genome. Total clinical WGS costs inclusive of analysis and reporting remain substantially higher, as documented in micro costing studies.

In 2010, Elaine Mardis posed a question that has become one of the most cited titles in genomic medicine: “The $1,000 Genome, the $100,000 Analysis?” Her framing identified a structural asymmetry: the cost of generating genomic data had collapsed, but not the cost in time, expertise, and infrastructure of interpreting that data. More than a decade later, this asymmetry remains the central challenge of clinical genomics.

“The bottleneck in genomic medicine is no longer sequencing. It is the transformation of sequence data into evidence-backed clinical interpretation.” — Mardis, Genome Med, 2010

The gap between sequencing and interpretation is not merely a computational problem. It is a multi-dimensional systems challenge involving continuously evolving knowledge bases, standardised classification frameworks, phenotype integration, and reporting infrastructure all of which must be maintained, versioned, and delivered at clinical speed and accuracy.

2. The Data Scale Problem: From Raw Variants to Clinical Signal

When a patient sample is processed through a germline or somatic sequencing pipeline, the output is a Variant Call Format (VCF) file, a structured text cataloguing every genomic position at which the patient’s sequence diverges from the human reference genome (GRCh38). The scale of this output is frequently underappreciated in clinical settings.

Analysis Type Variant Yield (post-filter) Clinically Actionable
Whole Exome Sequencing (WES) 30,000–100,000 variants ~3–5 findings per case
Whole Genome Sequencing (WGS) 3–5 million variants ~3–5 findings per case
Targeted Gene Panel Hundreds to thousands Panel and phenotype dependent

Sources: Bamshad et al., Nat Rev Genet, 2011; Turro et al., Nature, 2020

The challenge of variant prioritisation to reduce millions of candidates to a handful of clinically relevant findings is fundamentally a signal detection problem. The vast majority of observed variants are benign: common in healthy populations, synonymous in consequence, or well-characterised in curated databases. Achieving this reduction requires layered filtration: population allele frequency thresholds derived from large-scale reference cohorts such as gnomAD v4.1 (730,947 exomes and 76,215 genomes as of 2024), functional consequence annotation, zygosity assessment in context of the inheritance model, and evidence-based pathogenicity classification.

3. The Knowledge Currency Problem: Dynamic Databases in a Static Report

Clinical variant interpretation depends on a constellation of curated databases, each maintained by independent consortia and updated on distinct release cycles. The practical implications for a clinical genomics platform are substantial.

Database Content Update Cycle Key Reference
ClinVar Variant-disease interpretations from labs worldwide Continuous / weekly releases Landrum et al., 2016
gnomAD v4.1 Population allele frequencies from 730,947+ exomes Major releases ~1–2 yr Chen et al., 2024
OMIM Gene-disease relationships and phenotypic descriptions Continuous (daily) Amberger et al., 2019
HGMD Published germline mutations causing human disease Quarterly releases Stenson et al., 2017
ClinGen Gene-disease validity curations by expert panels Ongoing expert review Rehm et al., 2015
HPO (v2026) Human Phenotype Ontology, >18,000 structured terms Rolling releases Gargano et al., 2024
Orphanet Rare disease classification and gene associations Continuous curation orphanet.net

A variant classified as Uncertain Significance (VUS) at the time of initial reporting may be reclassified as Pathogenic or Likely Pathogenic as new functional evidence, segregation data, or case reports accumulate. Harrison et al. documented that ClinVar reclassification events occur regularly and have direct clinical consequences for patients. Managing this requires not simply querying databases but maintaining versioned, locally synchronised copies with differential update logic. Schema changes, identifier deprecations, and gene nomenclature updates compound this further.

“Inconsistent variant databases remain one of the most significant barriers to scalable clinical interpretation.” — Rehm et al., N Engl J Med, 2015

4. Variant Classification: Operationalising the ACMG/AMP Framework

The standard framework for germline variant classification is the 2015 ACMG/AMP joint consensus guideline authored by Richards et al. This framework defines five classification tiers — Pathogenic, Likely Pathogenic, Variant of Uncertain Significance (VUS), Likely Benign, and Benign — and provides 28 evidence criteria: PVS1, PS1–PS4, PM1–PM6, PP1–PP5 for pathogenic evidence (16 criteria total) and BA1, BS1–BS4, BP1–BP7 for benign evidence (12 criteria total).

Each criterion carries a defined evidence strength (very strong, strong, moderate, or supporting) and rules govern how criteria combine to reach a classification. Operationalising this at scale requires pre-computed in silico prediction scores from calibrated tools. For PP3 and BP4 (computational evidence criteria), the ClinGen Sequence Variant Interpretation (SVI) Working Group recommends calibrated tools including REVEL and BayesDel for missense variants, based on empirical calibration against benign and pathogenic training sets. SpliceAI is specifically used for splice-site evidence rather than PP3 for missense.

Inter-laboratory concordance remains a challenge. Shirts et al. demonstrated that classification discordance across laboratories is a meaningful source of clinical uncertainty. Eilbeck et al. similarly noted that variant prioritisation pipelines vary substantially in methodology and output.

5. Phenotype–Genotype Correlation: The Role of Clinical Context

Sequence-first variant interpretation achieves meaningful but limited diagnostic yields in rare disease settings. The 100,000 Genomes Project demonstrated that WGS achieves a diagnostic rate of approximately 25% (24.9%) in rare disease cohorts, with yield varying substantially by phenotype category.

A critical multiplier for diagnostic yield is phenotype-driven prioritisation: restricting candidate variant analysis to genes with established relevance to the patient’s clinical presentation. This requires structured phenotypic data entry using standardised ontologies, primarily the Human Phenotype Ontology (HPO), which by April 2026 comprises over 18,000 terms organised in a hierarchical graph structure.

Smedley et al. demonstrated that Exomiser, which integrates HPO-encoded phenotypes with variant pathogenicity evidence, significantly improves the ranking of causal variants relative to unguided approaches. The efficacy of such tools depends critically on the currency of underlying gene-disease association data from OMIM, Orphanet, and ClinGen, all of which require continuous updates and maintenance.

Key insight: Phenotype-to-genotype matching is not a one-time filter applied at the start of analysis. It is a dynamic, iterative process. A platform that re-evaluates gene-phenotype associations against updated ClinGen curations on every analysis run provides fundamentally different clinical value than one that applies static gene panels.

6. Computational Infrastructure: Pipelines, Parallelisation, and UI Performance

A tertiary analysis pipeline for a single WES sample encompasses variant annotation, classification scoring, phenotype-driven prioritisation, and report generation involving sequential and parallelisable steps across annotation databases that collectively occupy hundreds of gigabytes of indexed data. For a family trio (proband plus two parents), the computational graph expands to include de novo variant detection, co-segregation analysis, and compound heterozygosity phasing.

Clinical laboratories operating at scale require infrastructure that can autoscale compute resources per sample, queue and prioritise jobs by clinical urgency, guarantee reproducibility via containerised execution environments with pinned tool versions, and log provenance for every intermediate output.

Equally critical, but less discussed in the literature, is front-end performance. A clinical analyst reviewing a prioritised variant list expects real-time interaction: filtering, sorting, expanding transcript-level consequence data, and accessing supporting evidence all within a single interface. Rendering 10,000–80,000 annotated rows with responsive UI requires deliberate architectural choices: virtual DOM windowing, server-side indexed queries, lazy-loaded annotation panels, and pre-fetched evidence summaries.

7. Clinical Reporting: Standardisation Across Formats and Jurisdictions

The clinical genomics report is the final and most consequential output of the interpretation process. It must convey structured variant evidence to molecular pathologists, clinical geneticists, referring physicians, and patients. It must satisfy regulatory and accreditation requirements that differ by jurisdiction: CAP/CLIA in the United States and ISO 15189 in Europe and the United Kingdom.

ACMG clinical laboratory standards for next-generation sequencing (Rehm et al. 2013) explicitly address the requirement for standardised reporting, including genotype-phenotype correlation, classification criteria transparency, and variant nomenclature compliance. Generating varied institutional report formats from a single structured interpretation object without requiring analysts to manually reformat content remains an unsolved engineering challenge in most platforms.

Critical requirements include: HGVS-compliant variant nomenclature, explicit ACMG classification with criteria codes, evidence source citations with database version, inheritance model and segregation summary where applicable, and a narrative clinical interpretation. Traceability — the ability to reconstruct exactly which evidence was available and applied at the time of sign-out — is both a quality assurance requirement and a regulatory expectation.

8. What Vgen23 Is Building: Design Principles

Vgen23 is a clinical genomics platform designed to close the interpretation gap described above. It was built by a small dedicated team of scientists and engineers from clinical laboratories, from bioinformatics pipelines, and from the front lines of variant interpretation through iterative real-time development driven by feedback from real diagnostic labs.

The development process was not linear. Early versions of the annotation engine required complete rebuilds when ClinVar changed its submission schema. Classification logic was extended iteratively as edge cases, splice variants, multi-nucleotide variants, complex structural rearrangements revealed gaps in initial implementations.

Design Principle Implementation Detail
Evidence currency Automated synchronisation of ClinVar, gnomAD v4.1, OMIM, HGMD, ClinGen, HPO, and Orphanet with version tracking and differential update logic
Classification transparency Full ACMG/AMP criterion-level logging: criteria evaluated, evidence strength, source database version, and ClinGen SVI calibrated in silico tool scores
Phenotype integration HPO-based phenotype entry with Exomiser-style gene prioritisation, updated against current ClinGen gene-disease validity tiers
Scalable compute Containerised, parallelised pipeline execution with autoscaling and job-level provenance logging for every intermediate output
Responsive UI Virtualised variant tables, indexed server-side queries, and lazy-loaded annotation panels designed for clinical analyst throughput
Multi-format reporting Single structured interpretation object rendered to ACMG-style, CAP-compliant, and institution-specific report formats without manual reformatting
Traceability Every report version stamped with database versions, pipeline version, classification logic version, and complete analyst audit trail

9. Our Commitment to Clinical Laboratories

We are not a finished product. Clinical genomics is a field in which the science, the guidelines, and the databases are in continuous evolution. What we are committing to, explicitly and publicly, to every laboratory that trusts us with their cases:

  • Accuracy: Every variant classification backed by versioned, auditable evidence. Criteria applied transparently per current ACMG/AMP guidelines and ClinGen SVI updates.
  • Speed: From VCF upload to structured clinical report in hours, not weeks. Analyst time freed for interpretation and clinical judgment.
  • Traceability: Every finding linked to its evidence source, database version, and classification rationale. Reports remain reproducible and auditable years later.
  • Continuity: When ClinVar reclassifies a variant or ACMG updates guidelines, your platform reflects it. We carry the maintenance burden so your lab does not have to.

Thousands of patients move through clinical genomics laboratories each month, waiting for answers that the science already contains. The gap is not the biology. It is the infrastructure between the sequencer and the interpretation. We built Vgen23 to close that gap and we are committed to closing it, continuously, alongside every laboratory that chooses to work with us.

The future of genomic medicine is not faster sequencing. It is faster understanding. That is what we are building at Vgen23.

References

  1. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.
  2. Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program. National Human Genome Research Institute. [Accessed April 2026].
  3. Schwarze K, et al. The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single centre in the United Kingdom. Genet Med. 2020;22(1):85–94.
  4. Mardis ER. The $1,000 genome, the $100,000 analysis? Genome Med. 2010;2(11):84.
  5. den Dunnen JT, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37(6):564–569.
  6. Bamshad MJ, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet. 2011;12(11):745–755.
  7. Turro E, et al. Whole-genome sequencing of patients with rare diseases in a national health system. Nature. 2020;583(7814):96–102.
  8. Lek M, et al. Analysis of protein-coding genetic variation in 60,706 humans (ExAC). Nature. 2016;536(7616):285–291.
  9. Chen S, et al. A genomic mutational constraint map using variation in 76,156 human genomes (gnomAD v4.1). Nature. 2024;625:92–100.
  10. Landrum MJ, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016;44(D1):D862–D868.
  11. Amberger JS, et al. OMIM.org: Online Mendelian Inheritance in Man. Nucleic Acids Res. 2019;47(D1):D1038–D1043.
  12. Stenson PD, et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research. Hum Genet. 2017;136(6):665–677.
  13. Rehm HL, et al. ClinGen — The Clinical Genome Resource. N Engl J Med. 2015;372(23):2235–2242.
  14. Gargano MA, et al. The Human Phenotype Ontology in 2024. Nucleic Acids Res. 2024;52(D1):D1333–D1346.
  15. Harrison SM, et al. Using ClinVar as a resource to support variant interpretation. Curr Protoc Hum Genet. 2019;101(1):e93.
  16. Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and AMP. Genet Med. 2015;17(5):405–423.
  17. Pejaver V, et al. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria. Am J Hum Genet. 2022;109(12):2163–2177.
  18. Jaganathan K, et al. Predicting splicing from primary sequence with deep learning. Cell. 2019;176(3):535–548.
  19. Shirts BH, et al. Improving performance of multigene panels for genomic analysis of cancer predisposition. Genet Med. 2016;18(10):974–981.
  20. Eilbeck K, et al. Settling the score: variant prioritization and Mendelian disease. Nat Rev Genet. 2017;18(10):599–612.
  21. Smedley D, et al. Next-generation diagnostics and disease-gene discovery with the Exomiser. Nat Protoc. 2015;10(12):2004–2015.
  22. Rehm HL, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15(9):733–747.

Vgen23 supports qualified professionals in organising and standardising genomic analysis and reporting workflows. It does not provide a medical diagnosis. All outputs require professional review and sign-off.